Details of Disease

General Information of Disease (ID: DIS7K18Z)

• Disease Name: Herpes simplex virus infection
• Disease Class: 1F00: Herpes simplex infection
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS7K18Z: Herpes simplex virus infection
• ICD Code:
  ICD-11: ICD-11: 1F00
  ICD-10: ICD-10: B00
  ICD-9: ICD-9: 54
  Expand ICD-9: 54
• Disease Identifiers:
  MONDO ID: MONDO_0004609
  MESH ID: D006561
  UMLS CUI: C0019348
  MedGen ID: 9234
  SNOMED CT ID: 88594005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aciclovir	DMYLOVR	Approved	Small molecular drug	[1]
Docosanol	DMOHK1E	Approved	Small molecular drug	[2]
Idoxuridine	DMDRT0E	Approved	Small molecular drug	[3]
Isradipine	DMA5XGH	Approved	Small molecular drug	[4]
Valacyclovir Hydrochloride	DM5I1CE	Approved	Small molecular drug	[1]
Vidarabine	DM0N85H	Approved	Small molecular drug	[5]

This Disease is Treated as An Indication in 15 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ASP-2151	DM5N1OB	Phase 3	Small molecular drug	[6]
BAY 57-1293	DMSUB64	Phase 2	Small molecular drug	[7]
GEN-003	DMCS7YG	Phase 2	NA	[8]
Resiquimod	DML6XSP	Phase 2	Small molecular drug	[9]
SQX770	DMXPL3T	Phase 2	Small molecular drug	[10]
VCL-HB01	DMGMCCT	Phase 2	NA	[8]
Herpes simplex vaccine	DMNZP2K	Phase 1/2	NA	[11]
ACAM529	DM02QSU	Phase 1	NA	[12]
AG-707	DM7PLMJ	Phase 1	NA	[13]
Genital herpes therapy	DM66N3V	Phase 1	NA	[14]
Herpes simplex DNA vaccine	DMLK8RD	Phase 1	NA	[15]
HSV529	DMCA1AP	Phase 1	NA	[8]
ImmunoVEX HSV2	DMCSDEG	Phase 1	NA	[16]
LMV-601	DMV056J	Phase 1	Small molecular drug	[17]
MB-66	DMY3K8I	Phase 1	Antibody	[18]

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID28350212-Compound-7	DMUBSFV	Patented	Small molecular drug	[19]

This Disease is Treated as An Indication in 8 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PP-9706642	DMPOK89	Discontinued in Phase 2	NA	[20]
DISC-PRO	DMS0C61	Discontinued in Phase 1	NA	[21]
GT-3021	DMP8A2Z	Discontinued in Phase 1	NA	[22]
A-79296	DM3IYMF	Terminated	NA	[24]
BILD-1263	DMUOPBF	Terminated	Small molecular drug	[25]
BILD-1351	DMR01WE	Terminated	Small molecular drug	[26]
BILD-1357	DMZMUG2	Terminated	Small molecular drug	[27]
BILD-733	DMAU5WL	Terminated	Small molecular drug	[28]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Herpes simplex virus therapy	DM14UMF	Preclinical	NA	[23]

This Disease is Treated as An Indication in 16 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AdHSV-2	DM8SJ8A	Investigative	NA	[29]
AuroVax	DMSWB9Z	Investigative	NA	[29]
BJ-B11	DMBI3LW	Investigative	NA	[29]
CAL-102-R	DMF3K40	Investigative	NA	[29]
CAL-103-R	DM25DXJ	Investigative	NA	[29]
CY-301	DMOOXCC	Investigative	NA	[29]
DG-1-66	DM6CJLC	Investigative	NA	[29]
ELS-120	DMOUJI7	Investigative	NA	[29]
GD2-lm	DMMJJ3K	Investigative	NA	[29]
IDC-G103	DMOUZQX	Investigative	NA	[29]
Meganucleases	DMS15AG	Investigative	NA	[29]
PDS-0103	DMWQXXY	Investigative	NA	[29]
PN-201	DMGG359	Investigative	NA	[29]
Sacrovir	DM5FU8O	Investigative	NA	[29]
Tolecine	DMKK97Z	Investigative	NA	[29]
VN-180	DMORH6J	Investigative	NA	[29]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020941.
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 014169.
• [4] ClinicalTrials.gov (NCT00367211) Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.. U.S. National Institutes of Health.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4806).
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025919)
• [7] ClinicalTrials.gov (NCT01658826) Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5051).
• [10] ClinicalTrials.gov (NCT03521479) A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis. U.S. National Institutes of Health.
• [11] Herpes Simplex Virus Type 2 Vaccines: New Ground for Optimism . Clin Diagn Lab Immunol. 2004 May; 11(3): 437-445.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027853)
• [13] ClinicalTrials.gov (NCT00231049) Trial Evaluating Safety, Tolerability and Immune Response of AG-707. U.S. National Institutes of Health.
• [14] Clinical pipeline report, company report or official report of NanoBio Corp.
• [15] Clinical pipeline report, company report or official report of Pfizer.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031754)
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027176)
• [18] ClinicalTrials.gov (NCT02579083) Vaginal Antibody Safety Trial: Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of Herpes Simplex Virus (HSV) and Human Immunodeficiency Virus (HIV) (VAST). U.S. National Institutes of Health.
• [19] Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866.
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036329)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017112)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005712)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030565)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003585)
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004429)
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006827)
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009082)
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004139)
• [29] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.